Low-dose azacitidine maintenance therapy after allogeneic stem cell transplantation for high-risk pediatric acute myeloid leukemia

被引：21

作者：

Tamura, Akihiro ^{[1
]}

Ishida, Toshiaki ^{[1
]}

Saito, Atsuro ^{[1
]}

Yamamoto, Nobuyuki ^{[1
]}

Yokoi, Takehito ^{[1
,2
]}

Uemura, Suguru ^{[1
,3
]}

Nino, Nanako ^{[1
,3
]}

Fujiwara, Takahiro ^{[1
]}

Tahara, Teppei ^{[1
]}

Nakamura, Sayaka ^{[1
]}

Kozaki, Aiko ^{[1
]}

Kishimoto, Kenji ^{[1
]}

Hasegawa, Daiichiro ^{[1
]}

Kosaka, Yoshiyuki ^{[1
]}

机构：

[1] Kobe Childrens Hosp, Childrens Canc Ctr, Dept Hematol & Oncol, Kobe, Hyogo, Japan

[2] Osaka Univ Hosp, Dept Pediat, Suita, Osaka, Japan

[3] Kobe Univ Hosp, Dept Pediat, Kobe, Hyogo, Japan

来源：

PEDIATRIC BLOOD & CANCER | 2018年 / 65卷 / 10期

关键词：

acute myeloid leukemia; azacitidine; pediatric; post hematopoietic stem cell transplantation; CONVENTIONAL CARE REGIMENS; REGULATORY T-CELLS; MYELODYSPLASTIC SYNDROME; HYPOMETHYLATING AGENT; ELDERLY-PATIENTS; SALVAGE THERAPY; 5-AZA-2'-DEOXYCYTIDINE; MALIGNANCIES; DECITABINE; RELAPSE;

D O I：

10.1002/pbc.27284

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The dismal prognosis of pediatric acute myeloid leukemia (AML) relapsing after hematopoietic stem cell transplantation (HSCT) requires exploration of novel strategies to prevent relapse. Azacitidine (AZA) maintenance therapy could potentially reduce the recurrence rate post HSCT. Here, we presents the cases of three children with high-risk AML post HSCT who were treated with low-dose AZA maintenance therapy, demonstrating the feasibility of this therapy. Currently, all three are in complete remission for 13-41 months despite their high-risk characteristics. Our encouraging data warrant larger prospective studies to assess the efficacy and safety of low-dose AZA maintenance therapy post HSCT for pediatric patients with high-risk AML.

引用

页数：4

共 50 条

[31] Azacitidine for the treatment of patients with relapsed acute myeloid leukemia after allogeneic stem cell transplantation
Yoshimoto, Goichi
Mori, Yasuo
Kato, Koji
Odawara, Jun
Kuriyama, Takuro
Ueno, Toshiyuki
Obara, Teppei
Yurino, Ayano
Yoshida, Shuro
Ogawa, Ryosuke
Ohno, Yuju
Iwasaki, Hiromi
Eto, Tetsuya
Akashi, Koichi
Miyamoto, Toshihiro
LEUKEMIA & LYMPHOMA, 2021, 62 (12) : 2939 - 2948
[32] Maintenance therapy after allogeneic hematopoietic cell transplantation for acute myeloid leukemia
Appelbaum, Frederick R.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2019, 32 (04)
[33] Repetitively Administered Low-Dose Donor Lymphocyte Infusion for Prevention of Relapse after Allogeneic Stem Cell Transplantation in Patients with High-Risk Acute Leukemia
Tsirigotis, Panagiotis
Gkirkas, Konstantinos
Kitsiou, Vassiliki
Chondropoulos, Spiros
Athanassiades, Theofilos
Thomopoulos, Thomas
Tsirogianni, Alexandra
Stamouli, Maria
Karagiannidi, Aggeliki
Siafakas, Nikolaos
Pappa, Vassiliki
Nagler, Arnon
CANCERS, 2021, 13 (11)
[34] Epigenetic maintenance strategies after allogeneic stem cell transplantation in acute myeloid leukemia
Yan, Yu
Upadhyaya, Ram
Zhang, Vivian Weixuan
Berg, Tobias
EXPERIMENTAL HEMATOLOGY, 2022, 109 : 2 - +
[35] Phase II Trial of Venetoclax (Ven) in Combination with Azacitidine (AZA) As Maintenance Therapy for High-Risk Acute Leukemia Following Allogeneic Stem Cell Transplantation (SCT)
Oran, Betul
Champlin, Richard E.
Thall, Peter F.
McCarty, Jessica M.
Zhang, Wen
Marin, David
Mehta, Rohtesh S.
Alousi, Amin M.
Alatrash, Gheath
Popat, Uday R.
Kantarjian, Hagop
Bashir, Qaiser
Shpall, Elizabeth J.
Konopleva, Marina
BLOOD, 2022, 140 : 10561 - 10562
[36] A phase 1 dose-escalation study of low-dose lenalidomide maintenance post-allogeneic stem cell transplantation for high-risk acute myeloid leukaemia or myelodysplastic syndrome
Koo, Ray Mun
Wong, Eric
Davis, Joanne E.
Perera, Travis
Lim, Andrew
Koldej, Rachel M.
Ritchie, David S.
BONE MARROW TRANSPLANTATION, 2024, 59 (07) : 1025 - 1027
[37] Favorable Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Children With High-risk or Advanced Acute Myeloid Leukemia
Koh, Kyung Nam
Park, Meerim
Kim, Bo Eun
Bae, Keun Wook
Im, Ho Joon
Seo, Jong Jin
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2011, 33 (04) : 281 - 288
[38] Low-dose azacitidine for relapse prevention after allogeneic hematopoietic cell transplantation in children with myeloid malignancies
Oshrine, Benjamin R.
Shyr, David
Hale, Gregory
Petrovic, Aleksandra
PEDIATRIC TRANSPLANTATION, 2019, 23 (04)
[39] LOW-DOSE AZACITIDINE FOR RELAPSE PREVENTION AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN CHILDREN WITH MYELOID MALIGNANCIES
Oshrine, Benjamin
Shyr, David
Hale, Gregory
Petrovic, Aleksandra
PEDIATRIC BLOOD & CANCER, 2018, 65
[40] Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia
Craddock, Charles
Labopin, Myriam
Robin, Marie
Finke, Juergen
Chevallier, Patrice
Yakoub-Agha, Ibrahim
Bourhis, Jean Henri
Sengelov, Henrik
Blaise, Didier
Luft, Thomas
Hallek, Michael
Kroeger, Nicolaus
Nagler, Arnon
Mohty, Mohamad
HAEMATOLOGICA, 2016, 101 (07) : 879 - 883

← 1 2 3 4 5 →